68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report

Lung cancer still ranks first among the most common and most lethal cancers today. The most common subtype is non-small cell lung cancer, and in this group, adenocarcinoma has the worst prognosis. EGFR, ROS1 and ALK-EML4 gene fusion mutations are common in non-small cell lung cancer.In this article, we wanted to share our experience of crizotinib in a 68-months progression-free survival in a 62-years old non-smoking female patient with metastatic lung adenocarcinoma who is also diagnosed with sarcoidosis. READ ARTICLE

Journal of Oncology Pharmacy Practice DOI:10.1177/1078155220951242

Authors: Ozgur Tanriverdi, Mehmet L Tarimer, Ceren D Pak, Selcuk Uylas, Ali Alkan, Ozgur Ilhan Celik, Rabia M Kilic, Arife Zeybek

Case StudyKirk SmithAugust 23, 2021Lung adenocarcinoma, crizotinib, ALK-rearrangement, sarcoidosis, progression-free survival

Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma

Here, we describe a case study with confirmed EGFR wild-type and ALK-rearranged lung adenocarcinoma who developed complex renal cysts combined with hemorrhage during crizotinib treatment, with no abnormal clinical symptoms or kidney functions observed. Interestingly, without crizotinib treatment termination or reduction, the complex hemorrhagic renal cysts regressed with self-limiting and healing. The combined usage of ultrasound, CT and MRI techniques in the presented case allowed proper monitoring of the internal changes within complex renal cysts. The patient provided written informed consent authorizing publication of clinical case. Thus, better understanding of the imaging features of crizotinib-related renal cysts combined with hemorrhage would avoid misdiagnoses as a new metastatic renal mass or the aggravation of the primary disease, therefore avoiding further invasive investigation. READ ARTICLE

Cancer Treatment Research Communications DOI:10.1016/j.ctarc.2021.100373

Authors: Ling Yang, Jianing Gu, Xiaomin Niu

Case StudyKirk SmithApril 9, 2021ALK-rearrangement, crizotinib, NSCLC, Renal cysts, Self-limiting and healing